Xenetic Biosciences Extends Research Collaboration with Scripps Research to Advance DNase Platform
I'm PortAI, I can summarize articles.
Xenetic Biosciences Inc. has extended its research collaboration with The Scripps Research Institute and Dr. Alexey Stepanov’s laboratory for an additional four months starting November 1, 2025. The focus is on advancing Xenetic’s DNase I platform in combination with CAR T-cell therapies, aiming to improve responses to CAR-T cell therapy for hematologic and solid tumors. Preclinical studies have shown promising results, and the program is moving toward Phase 1 clinical development.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments